WR Hambrecht
VC Fund
San Francisco, United States
WR Hambrecht is a financial services firm that helps companies of all sizes access capital at the lowest cost in order to accelerate disruptive growth. Its philosophy is based on tenants such as identifying companies, helping them raise capital and go public, and delivering market pricing. The company has a wide range of products such as theOpenIPO Auction, the A+ IPO, the OpenBook Auction, and the OpenFollowOn Auction.Their clients are NETSUITE, Google, MORNINGSTAR, and XBiotech and it also offers initial public offering services to companies.WR Hambrecht is a U.S.-based company that was founded in 1998 by William and Robert Hambrecht.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 21%
- Fund size:
- $5M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries WR Hambrecht invests in
Stages WR Hambrecht invests in
Countries WR Hambrecht invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1M–$20M
- Series C
- $3.4M–$60M
Investment Focus
Industry
- Software 10 (24%)
- Health Care 9 (21%)
- Internet 7 (17%)
- Enterprise Software 4 (10%)
- Apps 3 (7%)
Stage
- Series A 13 (31%)
- Funding Round 9 (21%)
- Series C 7 (17%)
- Series B 4 (10%)
- Seed 3 (7%)
Country
- United States 34 (81%)
- Israel 2 (5%)
- China 1 (2%)
- France 1 (2%)
- Singapore 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
William Hambrecht
Founder & Chairman
|
Founder & Chairman | Total investments: 8 | Find email | |
|
Robert Hambrecht
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
Thomas Thurston
Partner, Chief Technology Officer
|
Partner, Chief Technology Officer | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Hone treats men's hormone imbalances and low testosterone with at-home lab testing, physician consultations, and medication | Series A / Sep 15, 2023 | ||
| Gabbi empowers women to understand their bodies and proactively seek the care they need. We use AI and clinical research to decrease the rate of preventable diseases and delayed diagnosis that affect women. Our proprietary risk model is the first-ever consumer facing platform that assesses a woman’s lifetime risk of disease, provides personalized& interactive action plans, and activates a community of engagement and support. | $4.4M / Seed / Oct 27, 2022 | ||
| Getlabs is the leading platform for at-home diagnostics.Healthcare organizations use Getlabs to send mobile phlebotomists to patients’ homes and collect labs, vitals, and advanced diagnostics. By leveraging Getlabs, partners can improve patient adherence and close gaps in care with same-day, nationwide availability.Our team has raised $50M fromstrategic investors including the two largest diagnostic laboratories in the United States, Labcorp and Quest. Getlabs’ mission is to save lives by expanding access to diagnostics for everyone. | $20M / Series A / Feb 03, 2022 | ||
| Aessense Holding is dedicated to providing solutions and technologies for both small and large-scale growth in a sustainable manner. It features unique growing stations, sensors, and wireless communications that empower growers to more efficiently, and effectively, grow their crops. | Series B / Jan 10, 2022 | ||
| Color is a population health technology company that focuses on providing large-scale health care programs and clinical testing. It improves the key health infrastructure systems to make health accessible, convenient, and cost-effective, serving health systems, employers, research institutions, and individual consumers.Its Population GenomicsPlatform offers modular and end-to-end solutions that enable organizations to effectively build and scale population health programs. It provides technology, software, and clinical services to help population programs launch and scale quickly. By combining innovative technology, specialized laboratory infrastructure, and clinical health services, Color creates complete and effective programs that include: Program strategy, planning, and implementation; Participant outreach and engagement; participant education and consent about testing and results; sample (blood or saliva) collection and genetic sequencing; data management and clinical reporting; HIPAA compliance and data security; return of results; clinical services, like genetic counseling and clinical pharmacy; personalized care routine; and ongoing population health management. Color’s partners include NorthShore University Health System, the National Institutes of Health (NIH), Ochsner Health System, Verily, Visa, Levi Strauss, and Salesforce.Elad Gil, Nish Bhat, Taylor Sittler, and Othman Laraki launched Color in 2015 and is based in Burlingame, California. | $100M / Series E / Nov 09, 2021 | ||
| Gabbi empowers women to understand their bodies and proactively seek the care they need. We use AI and clinical research to decrease the rate of preventable diseases and delayed diagnosis that affect women. Our proprietary risk model is the first-ever consumer facing platform that assesses a woman’s lifetime risk of disease, provides personalized& interactive action plans, and activates a community of engagement and support. | $1M / Seed / Jun 07, 2021 | ||
| PatientsLikeMe is a personalized health network of an integrated community, health management, and real-world data platform.It helps people find new options for treatments, connect with others, and take action to improve their outcomes. The company has worked with every major pharmaceutical company and a range of government organizations to bringthe patient voice to research, development, and public policy. With more than 600,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 100 research studies.The Boston, Massachusetts-located company was founded by Ben Heywood, James Heywood, and Jeff Cole in 2004 | $26M / Venture - Series Unknown / Feb 09, 2021 | ||
| Buoy provides a personalized all-in-one platform to help guide consumers back to health. Whether it's chatting about symptoms with Buoy Assistant to get help in the moment of sickness or researching benefits through Buoy Dashboard, Buoy is available 24/7 to help make self-diagnosis and navigating the healthcare system simple and easy. Foremployers, Buoy can be custom configured to surface benefits information and wellness programs, guide employees to in-network providers, and fully integrate with other health portals. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $37.5M / Series C / Nov 10, 2020 | ||
| Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including novel, humanizedmonoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. | $124.2M / Series C / Nov 05, 2020 | ||
| Finhabits offers investing, roth IRAs, traditional IRAs, financial habits, personal finance, fiduciary advice, and diversified portfolios. An online inquiry form is available on the company's website. | $5M / Seed / Apr 01, 2019 | ||
| See all 42 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does WR Hambrecht invest in?
WR Hambrecht invests primarily in Software, Health Care and Internet startups, most often at Series A and Funding Round stage. Most of the 42 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is WR Hambrecht's check size?
WR Hambrecht typically joins rounds of $1M–$20M at Series A and $3.4M–$60M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds WR Hambrecht participates in.
How do I contact WR Hambrecht?
Public channels for WR Hambrecht include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at WR Hambrecht?
The team at WR Hambrecht includes William Hambrecht (Founder & Chairman), Robert Hambrecht (Co-Founder) and Thomas Thurston (Partner, Chief Technology Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
